NCT07282392 Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)
| NCT ID | NCT07282392 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Utah |
| Condition | Lupus |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2028-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2028-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a psychotherapy intervention works to relieve widespread pain in patients with lupus. The main questions it aims to answer are: Is the psychotherapy treatment safe for lupus patients? Are lupus patients able to complete the treatment? Can the treatment help improve chronic pain and other symptoms in lupus patients? Researchers will compare the treatment to a control (participants who will continue their medical treatment but will not receive psychotherapy for the time frame of the treatment) to see if the psychotherapy treatment works to relieve widespread pain and other lupus-related symptoms. Participants will: Fill out questionnaires before and after the treatment. Participate in 8 weekly treatment sessions, 2 hours per session, delivered via Zoom from their own home. Keep a list of medications and monitor any changes in their medication regimen.
Eligibility Criteria
Inclusion Criteria: * Adults of all genders, ages 18-65. * A diagnosis of lupus and fibromyalgia or chronic widespread pain by a licensed rheumatologist * Be on a stable medication regimen. Exclusion Criteria: * Serious psychiatric disorders (e.g., schizophrenia or bipolar disorder) uncontrolled with medications. * Active suicidal ideation. * Untreated alcohol or substance use disorder. * Substantial cognitive impairment. * Changes in medications in the past 3 months. * Enrollment in another treatment study. * Current involvement in health-related litigation or disability application. * Inability to use a computer and/or smartphone. * limited access to the internet. * Inability to communicate in English. * Failure to complete the baseline assessments.
Contact & Investigator
Dan Kaufmann, PhD
PRINCIPAL INVESTIGATOR
University of Utah
Frequently Asked Questions
Who can join the NCT07282392 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Lupus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07282392 currently recruiting?
Yes, NCT07282392 is actively recruiting participants. Contact the research team at dan.kaufmann@hsc.utah.edu for enrollment information.
Where is the NCT07282392 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT07282392 clinical trial?
NCT07282392 is sponsored by University of Utah. The principal investigator is Dan Kaufmann, PhD at University of Utah. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.